Rani Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results; Provides Corporate Update
Rani Therapeutics Announces Preclinical Data Demonstrating Bioequivalence of RT-114, a GLP-1/GLP-2 Dual Agonist (PG-102) Delivered Orally via the RaniPill® Capsule, to Subcutaneously Administered PG-102
Rani Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results
Rani Therapeutics Holdings, Inc. (NASDAQ: RANI) had its "buy" rating re-affirmed by analysts at Canaccord Genuity Group Inc.. They now have a $9.00 price target on the stock.
Rani Therapeutics Holdings, Inc.'s (NASDAQ:RANI) largest shareholders are individual investors who were rewarded as market cap surged US$11m last week [Yahoo! Finance]